SM
EIGR

Sabby Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sabby Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5
Closed -$4.52M – 369
2015
Q1 		$4.52M Buy
+5
New +$43.7K 0.19% 86

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's EIGR Position: Q2 2018 in Review

Sabby Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2018, closing a stake of 1,073 shares — an estimated $317K sold.

Sabby Management first reported a position in EIGR in Q3 2014 and held it in 10 quarters. The position peaked at $4.35M in Q1 2016. 50 funds tracked by Wall St. Rank hold EIGR as of Q2 2018.

  • Sabby Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 1,073 Eiger BioPharmaceuticals, Inc. shares in Q2 2018, an estimated $317K.
  • Sabby Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
  • Sabby Management's Eiger BioPharmaceuticals, Inc. position peaked at $4.35M in Q1 2016.
  • 50 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.